Nachrichten zur United Therapeutics Corp Aktie

United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepags blockbuster potential.…

Image source: The Motley Fool.DATEWednesday, May 6, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Michael E. CastagnaChief Financial…

United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do…

…

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

Klinischer Meilenstein:  Die Aktie schießt unter hohem Volumen nach oben, nachdem die TETON-1-Studie für Tyvaso bei IPF den primären Endpunkt mit…

Durch die exzellenten Studiendaten vom 30.03.2026 steht United Therapeutics kurz davor, mit Tyvaso den Milliardenmarkt der idiopathischen pulmonalen Fibrose…

United Therapeutics (UTHR) hat sich mit dem Kernprodukt Tyvaso (Treprostinil) auf die Behandlung seltener Lungenerkrankungen spezialisiert. Zulassungen gibt es bereits…

Studie TETON-1 übertrifft Erwartungen:  Das Medikament Tyvaso zeigt bei der Behandlung von idiopathischer Lungenfibrose eine signifikante Verbesserung der Lungenfunktion.   Massives…

Jefferies raises United Therapeutics stock price target on trial data…

Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results…

United Therapeutics (UTHR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

…

United Therapeutics (UTHR) dürfte nun aus mehreren Gründen die Trendfortsetzung gelingen. Mit Tyvaso ist das Unternehmen zur Behandlung seltener Lungenerkrankungen…

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended December 2025,…

United Therapeutics (UTHR) delivered earnings and revenue surprises of +13.50% and -1.88%, respectively, for the quarter ended December 2025. Do…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis präsentiert Daten aus der Phase-2-Studie (EU) zu MELAS auf der Mitocon 2026Im Fokus stehen die…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Key PointsNew York City-based Summit Street Capital Management sold 281,812 shares of Kulicke and Soffa Industries in the third quarter.The…

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

United Therapeutics CFO Edgemond sells $9.4m in UTHR stock…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis meldet positive Zwischenergebnisse seiner Phase-II-Studie zu MELAS und gibt Pipeline-Fortschritte hinsichtlich Leigh-Syndrom und Cystinose bekanntIm…

Key PointsNepsis bought 92,916 shares of AAON for $8,682,071.The transaction represents a 2.75% change in 13F reportable assets under management…

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.…

United Therapeutics (UTHR) möchte mit der Behandlung von seltenen und lebensbedrohlichen Lungenerkrankungen sowie ab 2030 auch mit ersten Erlösen aus…

Key PointsGAAP revenue rose 12% year over year to $798.6 million in Q2 2025 but missed consensus by $3.27 million.GAAP…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis erhält positive Rückmeldung zur Einreichung eines IMPD für die klinische Phase-2a-Studie zu MASH bei Kindern…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis gibt zweites Prüfzentrum bekannt, beginnt mit der Rekrutierung für die klinische Phase-2-Studie MELAS und veröffentlicht…

…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis gibt FDA-Genehmigung für seinen Antrag auf Zulassung eines neuen Prüfpräparats (IND) für eine klinische Phase-2-Studie…

United Therapeutics (UTHR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

IRW-PRESS: Thiogenesis Therapeutics Corp.: Thiogenesis leitet klinische Phase-2-Studie zur mitochondrialen Enzephalomyopathie mit Laktatazidose und schlaganfallähnlichen Episoden (MELAS) einSan Diego, Kalifornien,…

MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies…

MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies…

United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.…

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

…

United Therapeutics (UTHR) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

United Therapeutics president Michael Benkowitz sells $3.57 million in stock…

We think all investors should try to buy and hold high quality multi-year winners. And weve seen some truly amazing...…

…

…

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.…

Stocks to watch include Uber Technologies and United Therapeutics.…